

NCANCER AGENT TREAKISYM

® INJECTION 100 MG

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") today launched the anticancer agent TREAKISYM[®] Injection 100 mg (generic name: bendamustine hydrochloride) in Japan as a treatment for low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma. TREAKISYM[®] is the first anticancer agent for Eisai to launch in Japan, and although it is already available in the United States, its Japan launch marks the company's fully-fledged entry into the Japanese oncology market.

SymBio Pharmaceuticals Limited (Headquarters: Tokyo, President & CEO: Fuminori Yoshida, "SymBio") received marketing approval for TREAKISYM[®] on October 27 of this year. The drug was today added to

Eisai positions oncology as a therapeutic area of focus

eribulin (generic name), the company's first in-house developed anticancer agent currently under regulatory review for the treatment of breast cancer, thereby making contributions to addressing the diversified needs of cancer patients and their families.

[Notes to editors]

1. About Bendamustine Hydrochloride

Bendamustine hydrochloride is an anticancer agent originally synthesized by German (formerly 'East German') pharmaceutical company Jenapharm and is marketed in Europe under the brand names Ribomustin[®] and Levact[®] as

3. Product Image

